Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.
UAE condemns Houthi missile attacks targeting Saudi Arabia
Gargash responds to Iran speaker's criticism of Nusseibeh UN bid
E611 lanes and Al Maktoum Airport tunnel to close for daytime testing
Dubai outlines five initiatives under Food Security Strategy 2030
UAE, Benin Presidents discuss development cooperation
